Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build

Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions

: Example of additional support material - test match for alicia, HIV and biktarvy - test video - XML Representation

Raw xml | Download


<DocumentReference xmlns="http://hl7.org/fhir">
  <id value="asm-alicia-example-2"/>
  <meta>
    <profile
             value="http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/AdditionalSupportMaterial"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: DocumentReference asm-alicia-example-2</b></p><a name="asm-alicia-example-2"> </a><a name="hcasm-alicia-example-2"> </a><a name="asm-alicia-example-2-en-US"> </a><p><b>RelatedMedicalIssue</b>: <span title="Codes:{http://snomed.info/sct 86406008}">Human immunodeficiency virus infection</span></p><p><b>identifier</b>: <code>http://example.org</code>/3</p><p><b>version</b>: 1.0</p><p><b>status</b>: Current</p><p><b>docStatus</b>: Final</p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/asm-category-cs AE}">Adverse Effects Management</span></p><p><b>subject</b>: <a href="Bundle-bundlepackageleaflet-da-94a96e39cfdcd8b378d12dd4063065f9.html#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">Bundle: identifier = https://www.gravitatehealth.eu/sid/doc#EU/1/18/1289/001; type = document; timestamp = 2023-06-27 10:09:22+0000</a></p><p><b>author</b>: hypertuny</p><p><b>description</b>: </p><div><p>Biktarvy, consisting of bictegravir, emtricitabine and tenofovir alafenamide, is a significant medication in the treatment of HIV and AIDS. This fixed-dose combination antiretroviral drug, approved for use in the United States in February 2018 and in the European Union in June 2018, is a combination therapy, often termed as highly active antiretroviral therapy. This therapy involves using two or more types of antiretroviral drugs. Each tablet of Biktarvy contains 50 milligrams bictegravir, 200 milligrams emtricitabine, and 25 milligrams tenofovir alafenamide, and is taken orally once daily.</p>
</div><blockquote><p><b>content</b></p><h3>Attachments</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Extension</b></td><td><b>ContentType</b></td><td><b>Language</b></td><td><b>Url</b></td><td><b>Title</b></td><td><b>Duration</b></td></tr><tr><td style="display: none">*</td><td/><td>text/html</td><td>English</td><td><a href="https://www.youtube.com/watch?v=HpndrPLs1Y8">https://www.youtube.com/watch?v=HpndrPLs1Y8</a></td><td>Biktarvy - Video explaining the medication and how it works.</td><td>715</td></tr></table></blockquote></div>
  </text>
  <extension
             url="http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/RelatedMedicalIssue">
    <valueCodeableReference>
      <concept>
        <coding>
          <system value="http://snomed.info/sct"/>
          <code value="86406008"/>
        </coding>
      </concept>
    </valueCodeableReference>
  </extension>
  <identifier>
    <system value="http://example.org"/>
    <value value="3"/>
  </identifier>
  <version value="1.0"/>
  <status value="current"/>
  <docStatus value="final"/>
  <category>
    <coding>
      <system
              value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/asm-category-cs"/>
      <code value="AE"/>
    </coding>
  </category>
  <subject>
    <reference
               value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
  </subject>
  <author>
    <display value="hypertuny"/>
  </author>
  <description
               value="Biktarvy, consisting of bictegravir, emtricitabine and tenofovir alafenamide, is a significant medication in the treatment of HIV and AIDS. This fixed-dose combination antiretroviral drug, approved for use in the United States in February 2018 and in the European Union in June 2018, is a combination therapy, often termed as highly active antiretroviral therapy. This therapy involves using two or more types of antiretroviral drugs. Each tablet of Biktarvy contains 50 milligrams bictegravir, 200 milligrams emtricitabine, and 25 milligrams tenofovir alafenamide, and is taken orally once daily."/>
  <content>
    <attachment>
      <extension
                 url="http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/VisualizationMethod">
        <valueCode value="video"/>
      </extension>
      <contentType value="text/html"/>
      <language value="en"/>
      <url value="https://www.youtube.com/watch?v=HpndrPLs1Y8"/>
      <title
             value="Biktarvy - Video explaining the medication and how it works."/>
      <duration value="715"/>
    </attachment>
  </content>
</DocumentReference>